PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Mental Health (UK). Borderline Personality Disorder: Treatment and Management. Leicester (UK): British Psychological Society; 2009. (NICE Clinical Guidelines, No. 78.)

12. REFERENCES

  • Abbass A, Sheldon A, Gyra J, et al. Intensive short-term dynamic psychotherapy for DSM-IV personality disorders: a randomized controlled trial. Journal of Nervous and Mental Disease. 2008;196:211–216. [PubMed: 18340256]
  • Aberg A, Cresswell T, Lidberg Y, et al. Two-year outcome of team-based intensive case management for patients with schizophrenia. Psychiatric Services. 1995;46:1263–1266. [PubMed: 8590112]
  • Achenbach TM. Manual for the Youth Self-Report and 1991 Profile . Burlington, Vermont: University of Vermont; 1991.
  • Achenbach TM. Manual for the Young Adult Self-Report and Young Adult Behavior Checklist. Burlington, Vermont: University of Vermont; 1997.
  • AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care. 2003;12:18–23. [PMC free article: PMC1743672] [PubMed: 12571340]
  • Alden LE, Wiggins JS, Pincus AL. Construction of circumplex scales for the Inventory of Interpersonal Problems. Journal of Personality Assessment. 1990;55:521–536. [PubMed: 2280321]
  • Alexander R, Cooray S. Diagnosis of personality disorders in learning disability. Br J Psychiatry Suppl. 2003;44:S28–S31. [PubMed: 12509306]
  • Alper G, Peterson SJ. Dialectical behavior therapy for patients with borderline personality disorder. Journal of Psychosocial Nursing and Mental Health Services. 2001;39:38–45. [PubMed: 11697073]
  • Andrea H, Bales D, Smits M. Mentalization based treatment in the Netherlands: Preliminary results. Unpublished. 2008
  • Antikainen R, Lehtonen J, Koponen H, et al. The effect of hospital treatment on depression and anxiety in patients with borderline personality organization. Nordic Journal of Psychiatry. 1992;46:399–405.
  • Antikainen R, Koponen H, Lehtonen J, et al. Factors predicting outcome of psychiatric hospital treatment in patients with borderline personality organization. Nordic Journal of Psychiatry. 1994;48:177–185.
  • Antikainen R, Hintikka J, Lehtonen J, et al. A prospective three-year follow-up study of borderline personality disorder inpatients. Acta Psychiatrica Scandinavica. 1995;92:327–335. [PubMed: 8619336]
  • APA. Diagnostic and Statistical Manual of Mental Disorders (3rd edition, revised) (DSM-III) Washington, DC: APA; 1987. 1987.
  • APA. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV) Washington, DC: APA; 1994.
  • APA. Handbook of Psychiatric Measures . Washington, DC: APA; 2000.
  • APA. Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry. 2001;158:1–52. [PubMed: 11665545]
  • Arntz A, van den Hoorn M, Cornelis J, et al. Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders. 2003;17:45–59. [PubMed: 12659546]
  • Atmaca M, Kuloglu M, Tezcan E, et al. Serum cholesterol and leptin levels in patients with borderline personality disorder. Neuropsychobiology. 2002;45:167–171. [PubMed: 12097803]
  • Audini B, Marks IM, Lawrence RE, et al. Home-based versus out-patient/in-patient care for people with serious mental illness. Phase II of a controlled study. British Journal of Psychiatry. 1994;165:204–210. [PubMed: 7953033]
  • Baldwin DS. Use of licensed medicines for unlicensed applications in psychiatric practice. Royal College of Psychiatrists’ Special Interest Group in Psychopharmacology; 2007. Available at: http://www​.rcpsych.ac.uk.
  • Barber M, Marzuk P, Leon A, et al. Aborted suicide attempts: a new classification of suicidal behavior. American Journal of Psychiatry. 1998;155:385–389. [PubMed: 9501750]
  • Barley W, Buie S, Peterson E, et al. Development of an inpatient cognitive-behavioral treatment program for borderline personality disorder. Journal of Personality Disorders. 1993;7:232–240.
  • Barnes TRE. A rating scale for drug-induced akathisia. British Journal of Psychiatry. 1989;154:672–676. [PubMed: 2574607]
  • Barratt EJ. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychological Reports. 1965;16:547–554. [PubMed: 14285869]
  • Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry. 1999;156:1563–1569. [PubMed: 10518167]
  • Bateman A, Fonagy P. Health service utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care. American Journal of Psychiatry. 2003;160:169–171. [PubMed: 12505818]
  • Bateman AW, Tyrer P. Services for personality disorder: organisation for inclusion. Advances in Psychiatric Treatment. 2004;10:425–433.
  • Beck AT, Ward DM, Mendelson M, et al. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571. [PubMed: 13688369]
  • Beck AT. Beck Hopelessness Scale . San Antonio, TX: The Psychological Corporation; 1988.
  • Beck AT, Steer RA. Manual for the Beck Scale for Suicide Ideation . San Antonio, TX: Psychological Corporation; 1991.
  • Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology. 1988;56:893–897. [PubMed: 3204199]
  • Becker DF, Grilo CM, Edell WS, et al. Diagnostic efficiency of borderline personality disorder criteria in hospitalized adolescents: comparison with hospitalized adults. American Journal of Psychiatry. 2002;159:2042–2047. [PubMed: 12450954]
  • Beecham J, Sleed M, Knapp M, et al. The costs and effectiveness of two psychosocial treatment programmes for personality disorder: a controlled study. European Psychiatry: the Journal of the Association of European Psychiatrists. 2006;21:102–109. [PubMed: 16140508]
  • Bellino S, Zizza M, Di Lorenzo R, et al. Combined therapy with interpersonal psychotherapy of major depressed patients: comparison between patients with borderline personality disorder and patients with other personality disorders. Italian Journal of Psychopathology. 2005;11:157–164.
  • Bellino S, Zizza M, Rinaldi C, et al. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie. 2006;51:453–460. [PubMed: 16838827]
  • Bellino S, Zizza M, Rinaldi C, et al. Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. Canadian Journal of Psychiatry –Revue Canadienne de Psychiatrie. 2007;52:718–725. [PubMed: 18399039]
  • Bemporad J, Smith H, Hanson G, et al. Borderline syndromes in childhood: criteria for diagnosis. American Journal of Psychiatry. 1982;139:596–602. [PubMed: 7072844]
  • Bemporad J, Smith HF, Hanson G. The borderline child, Basic Handbook of Child Psychiatry. Noshpitz J, editor. New York: Basic Books; 1987.
  • Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. American Journal of Psychiatry. 2001;158:295–302. [PubMed: 11156814]
  • Bender DS, Dolan RT, Skodol AE, et al. Prospective assessment of treatment use by patients with personality disorders. Psychiatric Services. 2006;57:254–257. [PMC free article: PMC2705621] [PubMed: 16452705]
  • Bender DS, Skodol AE, Dyck IR, et al. Ethnicity and mental health treatment utilization by patients with personality disorders. Journal of Consulting and Clinical Psychology. 2007;75:992–999. [PubMed: 18085915]
  • Berk MS, Jeglic E, Brown GK, et al. Characteristics of recent suicide attempters with and without borderline personality disorder. Archives of Suicide Research. 2007;11:91–104. [PubMed: 17178645]
  • Berkowitz CB, Gunderson JG. Multifamily psychoeducational treatment of borderline personality disorder, Multifamily Groups in the Treatment of Severe Psychiatric Disorders. McFarlane WR, editor. New York: Guilford; 2002. pp. 268–290.
  • Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet. 1997;350:185–186. [PubMed: 9250191]
  • Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. Journal of Nervous and Mental Disease. 1986;174:727–735. [PubMed: 3783140]
  • Bernstein EM, Putnam FW. An update on the Dissociative Experiences Scale. Dissociation. 1993;6:16–27.
  • Bernstein DP, Cohen P, Velez CN, et al. Prevalence and stability of the DSM III-R personality disorders in a community-based survey of adolescents. American Journal of Psychiatry. 1993;150:1237–1243. [PubMed: 8328570]
  • Bieling PJ, Antony MM, Swinson RP. The State-Trait Anxiety Inventory, Trait version: structure and content re-examined. Behaviour Research and Therapy. 1998;36:777–788. [PubMed: 9682533]
  • Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;(1):CD005653. [PubMed: 16437535]
  • Binks CA, Fenton M, McCarthy L, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;(1):CD005652. [PubMed: 16437534]
  • Black DW, Blum N, Letuchy E, et al. Borderline personality disorder and traits in veterans: psychiatric comorbidity, healthcare utilization, and quality of life along a continuum of severity. CNS Spectrums: The International Journal of Neuropsychiatric Medicine. 2006;11:680–689. [PubMed: 16946693]
  • Blum N, Pfohl B, St John D, et al. STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder. A preliminary report. Comprehensive Psychiatry. 2002;43:301–310. [PubMed: 12107867]
  • Blum N, St John D, Pfohl B, et al. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. American Journal of Psychiatry. 2008;165:468–478. [PMC free article: PMC3608469] [PubMed: 18281407]
  • Bogenschutz MP, George N. Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry. 2004;65:104–109. [PubMed: 14744178]
  • Bohus M. Health care utilisation of patients with borderline personality disorders in Germany. Personlichkeitsstorungen Theorie und Therapie. 2007;11:149–153.
  • Bohus M, Haaf B, Simms T, et al. Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behaviour Research and Therapy. 2004;42:487–499. [PubMed: 15033496]
  • Bond GR, Miller LD, Krumwied RD, et al. Assertive case management in three CMHCs: a controlled study. Hospital Community Psychiatry. 1988;39:411–418. [PubMed: 2836295]
  • Bond GR, Witheridge TF, Dincin J, et al. Assertive community treatment for frequent users of psychiatric hospitals in a large city: a controlled study. American Journal of Community Psychology. 1990;18:865–891. [PubMed: 2091459]
  • Bradley R, Conklin C, Westen D. The borderline personality diagnosis in adolescents: gender differences and subtypes. Journal of Child Psychology and Psychiatry. 2005;46:1006–1019. [PubMed: 16109003]
  • Bradley R, Jenei J, Westen D. Etiology of borderline personality disorder: disentangling the contributions of intercorrelated antecedents. Journal of Nervous and Mental Disease. 2005;193:24–31. [PubMed: 15674131]
  • Brazier J, Tumur I, Holmes M, et al. Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. Health Technology Assessment. 2006;10:iii, ix–iii, 117. [PubMed: 16959171]
  • Brent DA, Johnson B, Bartle S, et al. Personality disorder, tendency to impulsive violence, and suicidal behavior in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1993;32:69–75. [PubMed: 8428886]
  • Brodsky BS, Malone KM, Ellis SP, et al. Characteristics of borderline personality disorder associated with suicidal behavior. American Journal of Psychiatry. 1997;154:1715–1719. [PubMed: 9396951]
  • Brown GK, Newman CF, Charlesworth SE, et al. An open clinical trial of cognitive therapy for borderline personality disorder. Journal of Personality Disorders. 2004;18:257–271. [PubMed: 15237046]
  • Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. Journal of the American Medical Association. 2005;294:563–570. [PubMed: 16077050]
  • Bruscia KE. Defining Music Therapy. Gilsum: Barcelona Publishers; 1998.
  • Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. British Medical Journal. 2002;325:1332–1333. [PMC free article: PMC137809] [PubMed: 12468481]
  • Bush CT, Langford MW, Rosen P, et al. Operation outreach: intensive case management for severely psychiatrically disabled adults. Hospital Community Psychiatry. 1990;41:647–649. [PubMed: 2361668]
  • Buss AH, Durkee A. An inventory for assessing different kinds of hostility. Journal of Consulting Psychology. 1957;21:343–349. [PubMed: 13463189]
  • Buss AH, Perry M. The Aggression Questionnaire. Journal of Personality and Social Psychology. 1992;63:452–459. [PubMed: 1403624]
  • Byford S, Knapp M, Greenshields J, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychological Medicine. 2003;33:977–986. [PubMed: 12946082]
  • Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. Lamictal 602 study group. Journal of Clinical Psychiatry. 1999;60:79–88. [PubMed: 10084633]
  • Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex interventions to improve health. British Medical Journal. 2000;321:694–696. [PMC free article: PMC1118564] [PubMed: 10987780]
  • Carter G. Hunter Dialectical Behaviour Therapy Project. 2008. Unpublished report.
  • Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297:851–854. [PubMed: 12161658]
  • Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389. [PubMed: 12869766]
  • Chabrol H, Montovany A, Chouicha K. Frequency of borderline personality disorder in a sample of French high school students. Canadian Journal of Psychiatry. 2001;46:847–849. [PubMed: 11761637]
  • Chance S, Bakeman R, Kaslow N, et al. Core conflictual relationship themes in patients diagnosed with borderline personality disorder who attempted, or who did not attempt, suicide. Psychotherapy Research. 2000;10:337–355.
  • Chandler D, Hargreaves W, Spicer G, et al. Cost-effectiveness of a capitated assertive community treatment program. Psychiatric Rehabilitation Journal. 1997;22:327–336.
  • Chanen AM, Jackson HJ, McGorry PD, et al. Two-year stability of personality disorder in older adolescent outpatients. Journal of Personality Disorders. 2004;18:526–541. [PubMed: 15615665]
  • Chanen AM, Jovev M, Jackson HJ. Adaptive functioning and psychiatric symptoms in adolescents with borderline personality disorder. Journal of Clinical Psychiatry. 2007;68:297–306. [PubMed: 17335330]
  • Chanen AM, McCutcheon LK, Jovev M, et al. Prevention and early intervention for borderline personality disorder. Medical Journal of Australia. 2007;187:S18–S21. [PubMed: 17908019]
  • Chanen AM, Jackson HJ, McCutcheon LK, et al. Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: randomised controlled trial. The British Journal of Psychiatry. 2008;193:477–484. [PubMed: 19043151]

    This is the reference for study ID CHANEN2008.

  • Chanen AM, Jovev M, Djaja D, et al. Screening for borderline personality disorder in outpatient youth. Journal of Personality Disorders. 2008;22:353–364. [PubMed: 18684049]
  • Chanen AM, Jovev M, McCutcheon LK, et al. Borderline personality disorder in young people and the prospects for prevention and early intervention. Current Psychiatry Reviews. 2008;4:48–57.
  • Chen CK, Shiah I, Yeh CB, et al. Combination treatment of clozapine and topiramate in resistant rapid-cycling bipolar disorder. Clinical Neuropharmacology. 2005;28:136–138. [PubMed: 15965313]
  • Cheng AT, Mann AH, Chan KA. Personality disorder and suicide: a case-control study. British Journal of Psychiatry. 1997;170:441–446. [PubMed: 9307694]
  • Chiesa M. Different origins and meanings of acute acting-out in an inpatient psychotherapeutic setting. Psychoanalytic Psychotherapy. 1989;4:155–168.
  • Chiesa M, Fonagy P. Cassel Personality Disorder Study: methodology and treatment effects. British Journal of Psychiatry. 2000;176:485–491. [PubMed: 10912227]
  • Chiesa M, Fonagy P. Prediction of medium-term outcome in cluster B personality disorder following residential and outpatient psychosocial treatment. Psychotherapy and Psychosomatics. 2007;76:347–353. [PubMed: 17917470]
  • Chiesa M, Fonagy P, Holmes J, et al. Health service use costs by personality disorder following specialist and nonspecialist treatment: a comparative study. Journal of Personality Disorders. 2002;16:160–173. [PubMed: 12004492]
  • Chiesa M, Fonagy P, Holmes J, et al. Residential versus community treatment of personality disorders: a comparative study of three treatment programs. American Journal of Psychiatry. 2004;161:1463–1470. [PubMed: 15285974]
  • Chiesa M, Wright M, Leger D. Psychotropic medication and the therapeutic community: a survey of prescribing practices for severe personality disorder. Therapeutic Communities: International Journal for Therapeutic and Supportive Organisations. 2004;25:131–144.
  • Chiesa M, Fonagy P, Holmes J. Six-year follow-up of three treatment programs to personality disorder. Journal of Personality Disorders. 2006;20:493–509. [PubMed: 17032161]
  • Clarkin JF, Levy KN. Psychotherapy for patients with borderline personality disorder: focusing on the mechanisms of change. Journal of Clinical Psychology. 2006;62:405–410. [PubMed: 16470611]
  • Clarkin JF, Foelsch PA, Levy KN, et al. The development of a psychodynamic treatment for patients with borderline personality disorder: a preliminary study of behavioral change. Journal of Personality Disorders. 2001;15:487–495. [PubMed: 11778390]
  • Clarkin JF, Levy KN, Lenzenweger MF, et al. The Personality Disorders Institute/Borderline Personality Disorder Research Foundation randomized control trial for borderline personality disorder: rationale, methods, and patient characteristics. Journal of Personality Disorders. 2004;18:52–72. [PubMed: 15061344]
  • Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for Borderline Personality: Focusing on Object Relations . Washington, D.C: American Psychiatric Press; 2006.
  • Clarkin JF, Levy KN, Lenzenweger MF, et al. Evaluating three treatments for borderline personality disorder: a multiwave study. American Journal of Psychiatry. 2007;164:922–928. [PubMed: 17541052]
  • Coccaro EF, Harvey PD, Kupsaw-Lawrence E, et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. Journal of Neuropsychiatry and Clinical Neurosciences. 1991;3:S44–S51. [PubMed: 1821222]
  • Coccaro EF, Kavoussi RJ, Hauger RL, et al. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Archives of General Psychiatry. 1998;55:708–714. [PubMed: 9707381]
  • Coccaro EF, Lee R, McCloskey M. Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectrums: The International Journal of Neuropsychiatric Medicine. 2003;8:731–736. [PubMed: 14712171]
  • Cochrane Collaboration. Review Manager (RevMan) Version 428 for Windows. Oxford: The Cochrane Collaboration; 2005. [Computer programme]
  • Cohen P, Crawford TN, Johnson JG, et al. The children in the community study of developmental course of personality disorder. Journal of Personality Disorders. 2005;19:466–486. [PubMed: 16274277]
  • Cohen P, Chen H, Crawford T, et al. Personality disorders in early adolescence and the development of later substance use disorders in the general population. Drug and Alcohol Dependence. 2007;88:S71–S84. [PMC free article: PMC2034357] [PubMed: 17227697]
  • Coid J, Yang M, Tyrer P, et al. Prevalence and correlates of personality disorder in Great Britain. British Journal of Psychiatry. 2006;188:423–431. [PubMed: 16648528]
  • Comtois KA, Linehan M. Lifetime parasuicide count: description and psychometrics. Paper presented at the American Association of Suicidology Annual Conference; Houston, Texas. 1999.
  • Cooper P, Osborn M, Gath D, et al. Evaluation of a modified self-report measure of social adjustment. British Journal of Psychiatry. 1982;141:68–75. [PubMed: 7116075]
  • Copas J, O’Brien M, Roberts J, et al. Treatment outcome in personality disorder: the effect of social, psychological and behavioural variables. Personality and Individual Differences. 1984;5:565–573.
  • Corbitt EM, Malone KM, Haas GL, et al. Suicidal behavior in patients with major depression and comorbid personality disorders. Journal of Affective Disorders. 1996;39:61–72. [PubMed: 8835655]
  • Cottraux J, Note ID, Boutitie F, et al. Cognitive therapy versus rogerian supportive therapy in borderline personality disorder: a two-year follow-up of a controlled study. Unpublished. 2008 [PubMed: 19628959]
  • Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry. 1988;45:111–119. [PubMed: 3276280]
  • Crawford M, Rutter D, Price K, et al. Learning the Lessons: a Multi-Method Evaluation of Dedicated Community-Based Services For People With Personality Disorder. London: National Co-ordinating Centre for NHS Service Delivery and Organisation; 2007.
  • Crawford TN, Price K, Rutter D, et al. Dedicated community-based services for adults with personality disorder: Delphi study. The British Journal of Psychiatry. 2008;193:342–343. [PubMed: 18827303]
  • Creed F, Black D, Anthony P, et al. Randomised controlled trial of day patient versus inpatient psychiatric treatment. British Medical Journal. 1990;300:1033–1037. [PMC free article: PMC1662770] [PubMed: 2188696]
  • Creed F, Mbaya P, Lancashire S, et al. Cost effectiveness of day and inpatient psychiatric treatment: results of a randomised controlled trial. British Medical Journal. 1997;314:1381–1385. [PMC free article: PMC2126667] [PubMed: 9161310]
  • Crumley FE. Adolescent suicide attempts and borderline personality disorder: clinical features. Southern Medical Journal. 1981;74:546–549. [PubMed: 7244709]
  • Cunningham K, Wolbert R, Lillie B. It’s about me solving my problems: clients’ assessments of dialectical behavior therapy. Cognitive and Behavioral Practice. 2004;11:248–256.
  • Curtis L, Netten A. Unit Costs of Health and Social Care. Canterbury: PRSSU, University of Kent; 2003.
  • Daley SE, Hammen C, Burge D, et al. Depression and axis II symptomatology in an adolescent community sample: concurrent and longitudinal associations. Journal of Personality Disorders. 1999;13:47–59. [PubMed: 10228926]
  • Davidson KM. Cognitive Therapy for Personality Disorders: a Guide for Therapists . Oxford: Butterworth-Heinemann; 2000.
  • Davidson KM. Cognitive Therapy for Personality Disorders: a Guide for Clinicians. 2nd edn. London: Routledge; 2008.
  • Davidson K, Norrie J, Tyrer P, et al. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. Journal of Personality Disorders. 2006;20:450–465. [PMC free article: PMC1852259] [PubMed: 17032158]
  • Davidson K, Tyrer P, Gumley A, et al. A randomized controlled trial of cognitive behavior therapy for borderline personality disorder: rationale for trial, method, and description of sample. Journal of Personality Disorders. 2006;20:431–449. [PMC free article: PMC1847748] [PubMed: 17032157]
  • Davies S, Campling P. Therapeutic community treatment of personality disorder: service use and mortality over 3 years’ follow-up. Br J Psychiatry Suppl. 2003;44:S24–S27. [PubMed: 12509305]
  • Davies S, Campling P, Ryan K. Therapeutic community provision at regional and district levels. Psychiatric Bulletin. 1999;23:79–83.
  • Davison GC. Stepped care: doing more with less? Journal of Consulting and Clinical Psychology. 2000;68:580–585. [PubMed: 10965633]
  • De Cangas JPC. ‘Case management’ affirmatif: une evaluation complete d’un programme du genre en milieu hospitalier. Sante mentale au Quebec. 1994;19:75–92. [PubMed: 7795005]
  • De la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology. 1994;4:479–86. [PubMed: 7894258]
  • De la Fuente JM, Goldman S, Stanus E, et al. Brain glucose metabolism in borderline personality disorder. Journal of Psychiatric Research. 1997;31:531–541. [PubMed: 9368195]
  • Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine. 2002;21:1575–1600. [PubMed: 12111921]
  • Dekker J, Wijdenes W, Koning YA, et al. Assertive community treatment in Amsterdam. Community Mental Health Journal. 2002;38:425–434. [PubMed: 12236412]
  • Department of Health. The Mental Health Act: England and Wales. London: Department of Health; 1983.
  • Department of Health. Modernising Social Services: Promoting Independence, Improving Protection, Raising Standards. London: Department of Health; 1998.
  • Department of Health. Modern Standards and Service Models: National Service Framework for Mental Health. London: Department of Health; 1999.
  • Department of Health. The Future Organisation of Prison Health Care. Prison Service and NHS Executive Working Group. London: Department of Health; 1999.
  • Department of Health. Personality Disorder. No Longer a Diagnosis Of Exclusion. Policy Implementation Guidance for the Development Of Services For People With Personality Disorder. London: Department of Health; 2003.
  • Department of Health. Child and Adolescent Mental Health – National Service Framework for Children, Young People and Maternity Services. London: Department of Health; 2004.
  • Department of Health. Personality Disorder Capacity Plans 2005. London: Department of Health; 2006.
  • Derogatis LR. Brief Symptom Inventory (BSI): Administration, Scoring and Procedures Manual. 4th edn. Minneapolis, Minnesota: NCS Pearson Incorporation; 1993.
  • Derogatis LR. Brief Symptom Inventory, and matching clinical rating scales, Psychological Testing, Treatment Planning, and Outcome Assessment. Maruish M, editor. New York: Erlbaum; 1994.
  • Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behavioural Science. 1974;19:1–15. [PubMed: 4808738]
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed: 3802833]
  • Dick P, Ince A, Barlow M. Day treatment: suitability and referral procedure. British Journal of Psychiatry. 1985;147:250–253. [PubMed: 4063590]
  • Dixon L, McFarlane WR, Lefley H, et al. Evidence-based practices for services to families of people with psychiatric disabilities. Psychiatric Services. 2001;52:903–910. [PubMed: 11433107]
  • Dolan B. Gender Issues in Impulsive Behaviour; Paper presented at Perspectives on Women and Violence; London. 1991.
  • Dolan BM, Evans C, Wilson J. Therapeutic community treatment for personality disordered adults: changes in neurotic symptomatology on follow-up. International Journal of Social Psychiatry. 1992;38:243–250. [PubMed: 1493951]
  • Dolan BM, Warren FM, Menzies D, et al. Cost-offset following specialist treatment of severe personality disorders. Psychiatric Bulletin. 1996;40:413–417.
  • Dolan B, Warren F, Norton K. Change in borderline symptoms one year after therapeutic community treatment for severe personality disorder. British Journal of Psychiatry. 1997;171:274–279. [PubMed: 9337984]
  • Donegan NH, Sanislow CA, Blumberg HP, et al. Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biological Psychiatry. 2003;54:1284–1293. [PubMed: 14643096]
  • Drake RE, McHugo GJ, Clark RE, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. American Journal of Orthopsychiatry. 1998;68:201–215. [PubMed: 9589759]
  • Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal. 1996;313:275–283. [PMC free article: PMC2351717] [PubMed: 8704542]
  • Dursan SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. European Neuropsychopharmacology. 2000;4:479–486.
  • D’Zurilla TJ, Goldfried MR. Problem solving and behavior modification. Journal Abnormal Psychology. 1971;78:107–126. [PubMed: 4938262]
  • Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: methods of developing guidelines for efficient drug use in primary care. British Medical Journal. 1998;316:1232–1235. [PMC free article: PMC1112989] [PubMed: 9553004]
  • Eli Lilly. Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: a Randomized Double-Blind Comparison with Placebo, #6253. Unpublished.
  • Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry. 1976;33:766–771. [PubMed: 938196]
  • Eren N, Ozdemir O, Ogunc N, et al. Borderline hastalarla yapilan dinamik yönelimli sanat psikoterapi grubunda sürecin deg erlendirilmesi. [Evaluation of the dynamic oriented art psychotherapy group process in borderline patients] Psikiyatri Psikoloji Psikofarmakoloji Dergisi. 2000;8:285–294.
  • Essock SM, Kontos N. Implementing assertive community treatment teams. Psychiatric Services. 1995;46:679–683. [PubMed: 7552558]
  • Euro-Qol Group. Euro-Qol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. [PubMed: 10109801]
  • Evans K, Tyrer P, Catalan J, et al. Manual-assisted cognitive-behaviour therapy (MACT): a randomized controlled trial of a brief intervention with bibliotherapy in the treatment of recurrent deliberate self-harm. Psychological Medicine. 1999;29:19–25. [PubMed: 10077290]
  • Fagin L. Management of personality disorders in acute in-patient settings. Part 1: borderline personality disorders. Advances in Psychiatric Treatment. 2004;10:93–99.
  • Fava M. Prospective studies of adverse events related to antidepressant discontinuation. Journal of Clinical Psychiatry. 2006;67(Suppl 4):14–21. [PubMed: 16683858]
  • Feigenbaum JD, Fonagy P, Pilling S, et al. A pilot randomised control trial of the effectiveness of dialectical behavioural therapy (DBT) for Cluster B personality disorder. Unpublished. 2008
  • Fekete DM, Bond GR, McDonel EC, et al. Rural assertive community treatment: a field experiment. Psychiatric Rehabilitation Journal. 1998;21:371–379.
  • Fenton FR, Tessier L, Struening EL. A comparative trial of home and hospital psychiatric care. One-year follow-up. Archives of General Psychiatry. 1979;36:1073–1079. [PubMed: 475542]
  • Fenton WS, Mosher LR, Herrell JM, et al. Randomized trial of general hospital and residential alternative care for patients with severe and persistent mental illness. American Journal of Psychiatry. 1998;155:516–522. [PubMed: 9545998]
  • Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry. 2000;47:8–21. [PubMed: 10650444]
  • Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl-eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry. 2001;158:2071–2074. [PubMed: 11729030]
  • First MB, Gibbon M, Spitzer RL, et al. The Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) Washington, DC: American Psychiatric Press; 1997.
  • Fischer M, Barkley RA, Smallish L, et al. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. Journal of Abnormal Child Psychology. 2002;30:463–475. [PubMed: 12403150]
  • Floru L, Heinrich K, Wittek F. The problem of post-psychotic schizophrenic depressions and their pharmacological induction. International Pharmacopsychiatry. 1975;10:230–239. [PubMed: 814106]
  • Flynn A, Matthews H, Hollins S. Validity of the diagnosis of personality disorder in adults with learning disability and severe behavioural problems. Preliminary study. British Journal of Psychiatry. 2002;180:543–546. [PubMed: 12042234]
  • Fonagy P, Bateman A. Mentalizing and borderline personality disorder. Journal of Mental Health. 2007;16:83–101.
  • Fonagy P, Target M, Gergely G, et al. The developmental roots of borderline personality disorder in early attachment relationships: a theory and some evidence. Psychoanalytic Inquiry. 2003;23:412–459.
  • Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry. 2002;63:442–446. [PubMed: 12019669]
  • Freeman MP. Omega-3 fatty acids in psychiatry: a review. Annals of Clinical Psychiatry. 2000;12:159–165. [PubMed: 10984006]
  • Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry. 2006;67:1954–1967. [PubMed: 17194275]
  • Friedman RA, Leon AC. Expanding the black box – depression, antidepressants, and the risk of suicide. New England Journal of Medicine. 2007;356:2343–2346. [PubMed: 17485726]
  • Friedman RC, Corn R. Suicide and the borderline depressed adolescent and young adult. Journal of the American Academy of Psychoanalysis. 1987;15:429–448. [PubMed: 3667385]
  • Fruzzetti AE, Shenk C, Lowry K, et al. Emotion regulation, Cognitive Behaviour Therapy: Applying Empirically Supported Techniques In Your Practice. O’Donohue WT, Fisher JE, Hayes SC, editors. New York: Wiley; 2003.
  • Fruzzetti AE, Shenk C, Hoffman PD. Family interaction and the development of borderline personality disorder: a transactional model. Development and Psychopathology. 2005;17:1007–1030. [PubMed: 16613428]
  • Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology. 2006;59:7–10. [PubMed: 16360555]
  • Fyer MR, Frances AJ, Sullivan T, et al. Comorbidity of borderline personality disorder. Archives of General Psychiatry. 1988;45:348–352. [PubMed: 3355321]
  • Fyer MR, Frances AJ, Sullivan T, et al. Suicide attempts in patients with borderline personality disorder. American Journal of Psychiatry. 1988;145:737–739. [PubMed: 3369563]
  • Gabbard GO, Coyne L, Allen JG, et al. Evaluation of intensive inpatient treatment of patients with severe personality disorders. Psychiatric Services. 2000;51:893–898. [PubMed: 10875954]
  • Garland MR, Hallahan B. Essential fatty acids and their role in conditions characterised by impulsivity. International Review of Psychiatry. 2006;18:99–105. [PubMed: 16777664]
  • Garnet KE, Levy KN, Mattanah JJ, et al. Borderline personality disorder in adolescents: ubiquitous or specific? American Journal of Psychiatry. 1994;151:1380–1382. [PubMed: 8067498]
  • George A, Soloff PH. Schizotypal symptoms in patients with borderline personality disorder. American Journal of Psychiatry. 1986;143:212–215. [PubMed: 3946657]
  • Geraghty R, Warren F. Ethnic diversity and equality of access to specialist therapeutic community treatment for severe personality disorder. Psychiatric Bulletin. 2003;27:453–456.
  • Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of General Psychiatry. 2006;63:649–658. [PubMed: 16754838]
  • Gilroy A. Art Therapy, Research and Evidence Based Practice . London: Sage Publications; 2006.
  • Glick ID, Fleming L, DeChillo N, et al. A controlled study of transitional day care for non-chronically-ill patients. American Journal of Psychiatry. 1986;143:1551–1556. [PubMed: 3789208]
  • Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry. 1986;43:680–686. [PubMed: 3521531]
  • Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry. 1992;149:1148–1156. [PubMed: 1386964]
  • Gottschalk G, Boekholt C. Body-therapeutic work with borderline patients. PTT: Personlichkeitsstorungen Theorie und Therapie. 2004;8:154–160.
  • GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal. 2004;328:1490–1497. [PMC free article: PMC428525] [PubMed: 15205295]
  • Gregory RJ, Chlebowski S, Kang D, et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorders. Psychotherapy: Theory, Research, Practice, Training. 2008;45:28–41. [PubMed: 22122363]
  • Grilo CM, McGlashan TH, Skodol AE. Stability and course of personality disorders: the need to consider comorbidities and continuities between axis I psychiatric disorders and axis II personality disorders. Psychiatric Quarterly. 2000;71:291–307. [PubMed: 11025909]
  • Grilo CM, Becker DF, Edell WS, et al. Stability and change of DSM-III-R personality disorder dimensions in adolescents followed up 2 years after psychiatric hospitalization. Comprehensive Psychiatry. 2001;42:364–368. [PubMed: 11559862]
  • Gross R, Olfson M, Gameroff M, et al. Borderline personality disorder in primary care. Archives of Internal Medicine. 2002;162:53–60. [PubMed: 11784220]
  • Gunderson JG, Kolb JE. Discriminating features of borderline patients. American Journal of Psychiatry. 1978;135:792–796. [PubMed: 665789]
  • Gunderson JG, Shea MT, Skodol AE, et al. The Collaborative Longitudinal Personality Disorders Study: development, aims, design, and sample characteristics. Journal of Personality Disorders. 2000;14:300–315. [PubMed: 11213788]
  • Gunderson JG, Daversa MT, Grilo CM, et al. Predictors of 2-year outcome for patients with borderline personality disorder. American Journal of Psychiatry. 2006;163:822–826. [PubMed: 16648322]
  • Guy W. ECDEU Assessment Manual for Psychopharmacology, US Department of Health, Education, and Welfare Publication (ADM) Rockville, MD: National Institute of Mental Health; 1976. pp. 76–338.
  • Hafner RJ, Holme G. The influence of a therapeutic community on psychiatric disorder. Journal of Clinical Psychology. 1996;52:461–468. [PubMed: 8842884]
  • Haigh R. Services for people with personality disorder: the thoughts of service users. 2002. [accessed 10 April 2008]. Available at: http://www​.dh.gov.uk​/en/Publicationsandstatistics​/Publications​/PublicationsPolicyAndGuidance​/DH_4009546.
  • Haigh R. The 16 personality disorder pilot projects. Mental Health Review Journal. 2007;12:29–39.
  • Haigh R, Lees J. Fusion therapeutic communities: divergent histories, converging challenges. Therapeutic Communities: International Journal for Therapeutic and Supportive Organisations. 2008 in press.
  • Haigh R, Tucker S. Democratic development of standards: the community of communities—a quality network of therapeutic communities. Psychiatric Quarterly. 2004;75:263–277. [PubMed: 15335229]
  • Haigh R, Worrall A. The Principles and Therapeutic Rationale of Therapeutic Communities. 2002. Unpublished.
  • Hall J, Caleo S, Stevenson J, et al. An economic analysis of psychotherapy for borderline personality disorder patients. Journal of Mental Health Policy and Economics. 2001;4:3–8. [PubMed: 11967460]
  • Hallahan B, Hibbeln JR, Davis JM, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single centre double-blind randomised controlled trial. British Journal of Psychiatry. 2007;190:118–122. [PubMed: 17267927]
  • Hamilton CE. Continuity and discontinuity of attachment from infancy through adolescence. Child Development. 2000;71:690–694. [PubMed: 10953935]
  • Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959;32:50–55. [PubMed: 13638508]
  • Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62. [PMC free article: PMC495331] [PubMed: 14399272]
  • Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry. 2006;63:332–339. [PubMed: 16520440]
  • Hampton B, Korr W, Bond GR, et al. Integration Services System Approach to Avert Homelessness, CSP Homeless Prevention Project for HMI Adults, State of Illinois NIMH Demonstration Grant program, Final report. 1992.
  • Hargreaves WA. Systematic Nurses’ Observation of Psychopathology. Archives of General Psychiatry. 1968;10:518–531. [PubMed: 5647531]
  • Harley RM, Baity MR, Blais MA, et al. Use of dialectical behavior therapy skills training for borderline personality disorder in a naturalistic setting. Psychotherapy Research. 2007;17:351–358.
  • Hart SD. Forensic issues, Handbook of Personality Disorder. Livesley WJ, editor. London: Guilford; 2001.
  • Havsteen-Franklin D. Differentiating the ego-personality and internal other in art psychotherapy with patients with borderline personality disorder. Psychodynamic Practice. 2007;13:59–83.
  • Hawton K, Kirk JW. Problem solving, Cognitive Behaviour Therapy for Psychiatric Problems: A Practical Guide. Hawton K, Salkovskis PM, Kirk JW, et al., editors. Oxford: Oxford Medical Publications; 1989.
  • Helgeland MI, Torgersen S. Developmental antecedents of borderline personality disorder. Comprehensive Psychiatry. 2004;45:138–147. [PubMed: 14999665]
  • Helgeland MI, Kjelsberg E, Torgersen S. Continuities between emotional and disruptive behavior disorders in adolescence and personality disorders in adulthood. American Journal of Psychiatry. 2005;162:1941–1947. [PubMed: 16199842]
  • Hellgren L, Gillberg IC, Bagenholm A, et al. Children with deficits in attention, motor control and perception (DAMP) almost grown up: psychiatric and personality disorders at age 16 years. Journal of Child Psychology & Psychiatry & Allied Disciplines. 1994;35:1255–1271. [PubMed: 7806609]
  • Hengeveld MW, Jonker DJL, Rooijmans HGM. A pilot study of a short cognitive-behavioral group treatment for female recurrent suicide attempters. International Journal of Psychiatry in Medicine. 1996;26:83–91. [PubMed: 8707457]
  • Herinckx HA, Kinney RF, Clarke GN, et al. Assertive community treatment versus usual care in engaging and retaining clients with severe mental illness. Psychiatric Services. 1997;48:1297–1306. [PubMed: 9323749]
  • Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biological Psychiatry. 2001;50:292–298. [PubMed: 11522264]
  • Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry. 2007;8:212–244. [PubMed: 17963189]
  • Herz MI, Endicott J, Spitzer RL, et al. Day versus inpatient hospitalization: a controlled study. American Journal of Psychiatry. 1971;127:1371–1382. [PubMed: 5549929]
  • Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. [PubMed: 12111919]
  • HMSO. Children Act 1989. London: The Stationery Office; 1989. Available at: http://www​.opsi.gov.uk​/acts/acts1989/Ukpga_19890041_en_1.
  • HMSO. Children Act 2004. London: The Stationery Office; 2004. Available at: http://www​.opsi.gov.uk​/acts/acts2004/pdf/ukpga_20040031_en​.pdf.
  • HMSO. The Mental Capacity Act 2005. London: The Stationery Office; 2005. Available at: http://www​.opsi.gov.uk​/acts/acts2005/ukpga_20050009_en_1.
  • HMSO. The Mental Health Act 2007. London: The Stationery Office; 2007. Available at: http://www​.opsi.gov.uk​/acts/acts2007/ukpga_20070012_en_1.
  • Hobson RF. Forms of Feeling: The Heart of Psychotherapy. London: Tavistock Publications; 1985.
  • Hodgetts A, Wright J, Gough A. Clients with borderline personality disorder: exploring their experiences of dialectical behaviour therapy. Counselling and Psychotherapy Research. 2007;7:172–177.
  • Hoffman P, Buteau E, Hooley J, et al. Family members’ knowledge about borderline personality disorder: correspondence with their levels of depression, burden, distress, and expressed emotion. Family Process. 2003;42:469–478. [PubMed: 14979218]
  • Hoffman PD, Struening E, Buteau E, et al. Family Perspectives Survey. 2005
  • Hoffman PD, Buteau E, Fruzzetti AE. Borderline personality disorder: Neo-personality inventory ratings of patients and their family members. International Journal of Social Psychiatry. 2007;53:204–215. [PubMed: 17569406]
  • Hoffman PD, Fruzzetti AE, Buteau E. Understanding and engaging families: An education, skills and support programme for relatives impacted by borderline personality disorder. Journal of Mental Health. 2007;16:69–82.
  • Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry. 2001;62:199–203. [PubMed: 11305707]
  • Hollander E, Tracey KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186–1197. [PubMed: 12700713]
  • Holmes J. Psychotherapeutic approaches to the management of severe personality disorder in general psychiatric settings. CPD Bulletin Psychiatry. 1999;1:35–41.
  • Hooley JM, Hoffman PD. Expressed emotion and clinical outcome in borderline personality disorder. American Journal of Psychiatry. 1999;156:1557–1562. [PubMed: 10518166]
  • Horesh N, Sever J, Apter A. A comparison of life events between suicidal adolescents with major depression and borderline personality disorder. Comprehensive Psychiatry. 2003;44:277–283. [PubMed: 12923705]
  • Horesh N, Orbach I, Gothelf D, et al. Comparison of the suicidal behavior of adolescent inpatients with borderline personality disorder and major depression. Journal of Nervous and Mental Disease. 2003;191:582–588. [PubMed: 14504567]
  • Horn N, Johnstone L, Brooke S. Some service user perspectives on the diagnosis of borderline personality disorder. Journal of Mental Health. 2007;16:255–269.
  • Horowitz LM, Rosenberg SE, Baer BA, et al. Inventory of interpersonal problems: psychometric properties and clinical applications. Journal of Consulting and Clinical Psychology. 1988;56:885–892. [PubMed: 3204198]
  • Horwitz AV, Widom CS, McLaughlin J, et al. The impact of childhood abuse and neglect on adult mental health: a prospective study. Journal of Health and Social Behaviour. 2001;42:184–201. [PubMed: 11467252]
  • Hoult J, Reynolds I, Charbonneau-Powis M, et al. A controlled study of psychiatric hospital versus community treatment – the effect on relatives. Australian New Zealand Journal of Psychiatry. 1981;15:323–328. [PubMed: 6951573]
  • House of Lords. Bolitho v City and Hackney Health Authority. 1997. Available at: http://www​.publications​.parliament.uk/pa​/ld199798/ldjudgmt/jd971113/boli01.htm.
  • Huband N, McMurran M, Evans C, et al. Social problem-solving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial. British Journal of Psychiatry. 2007;190:307–313. [PubMed: 17401036]
  • Hulbert C, Thomas R. Public sector group treatment for severe personality disorder: a 12-month follow-up study. Australasian Psychiatry. 2007;15:226–231. [PubMed: 17516186]
  • Hummelen B, Wilberg T, Karterud S. Interviews of female patients with borderline personality disorder who dropped out of group psychotherapy. International Journal of Group Psychotherapy. 2007;57:67–91. [PubMed: 17266430]
  • Hyler SE. PDQ-4 + Personality Questionnaire. NewYork: Author; 1994.
  • Isohanni M, Nieminen P. Predicting immediate outcome on a closed psychiatric ward functioning as a therapeutic community. Psychiatria Fennica. 1989;1989:13–22.
  • Isohanni M, Nieminen P. Relationship between involuntary admission and the therapeutic process in a closed ward functioning as a therapeutic community. Acta Psychiatrica Scandinavica. 1990;81:240–244. [PubMed: 2343746]
  • Isohanni M, Nieminen P. The determinants of therapeutic community activity at an acute patients’ psychiatric ward. International Journal of Therapeutic Communities. 1990;11:140–148.
  • Jadad AR, Moore RA, Carroll D. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17:1–12. [PubMed: 8721797]
  • Jakubczyk A, Zechowski C, Namyslowska I. Treatment of adolescent borderline patients in a psychiatric unit. Archives of Psychiatry and Psychotherapy. 2001;3:65–72.
  • Jeffrey W. Pathology enhancement in the therapeutic community. International Journal of Social Psychiatry. 1985;31:110–118. [PubMed: 4008183]
  • Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. Journal of Nervous and Mental Disease. 1995;183:566–576. [PubMed: 7561818]
  • Johnson DA. Studies of depressive symptoms in schizophrenia: the prevalence of depression and its possible causes. British Journal of Psychiatry. 1981;139:546–552.
  • Johnson JG, Cohen P, Brown J, et al. Childhood maltreatment increases risk for personality disorders during early adulthood. Archives of General Psychiatry. 1999;56:600–606. [PubMed: 10401504]
  • Johnson JG, Cohen P, Skodol AE, et al. Personality disorders in adolescence and risk of major mental disorders and suicidality during adulthood. Archives of General Psychiatry. 1999;56:805–811. [PubMed: 12884886]
  • Johnson JG, Cohen P, Gould MS, et al. Childhood adversities, interpersonal difficulties, and risk for suicide attempts during late adolescence and early adulthood. Archives of General Psychiatry. 2002;59:741–749. [PubMed: 12150651]
  • Johnson S, Nolan F, Pilling S, et al. Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. British Medical Journal. 2005;331:599. [PMC free article: PMC1215550] [PubMed: 16103032]
  • Jones JM, Pearson GT, Dimpero R. Long-term treatment of the hospitalized adolescent and his family: an integrated systems-theory approach. Adolescent Psychiatry. 1989;16:449–472. [PubMed: 2817269]
  • Jones V, Stafford C. How accessible are personality disorder services for black and minority ethnic people? Therapeutic Communities: the International Journal for Therapeutic and Supportive Organizations. 2007;28:329–332.
  • Joyce PR, McKenzie JM, Carter JD, et al. Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. British Journal of Psychiatry. 2007;190:503–508. [PubMed: 17541110]
  • Karterud S, Vaglum S, Friis S, et al. Day hospital therapeutic community treatment for patients with personality disorders: an empirical evaluation of the containment function. Journal of Nervous an Mental Disease. 1992;180:238–243. [PubMed: 1556563]
  • Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276. [PubMed: 3616518]
  • Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry. 1987;44:540–548. [PubMed: 3579500]
  • Kendell RE. The distinction between personality disorder and mental illness. British Journal of Psychiatry. 2002;180:110–115. [PubMed: 11823318]
  • Kennard D, Haigh R. Therapeutic Communities . Oxford; Oxford University Press; 2009. In press.
  • Kernberg O. Borderline personality organization. Journal of the American Psychoanalytic Association. 1967;15:641–685. [PubMed: 4861171]
  • Kernberg O. Borderline Conditions and Pathological Narcissism . New York: Jason Aronson; 1975.
  • Kernberg O, Haran C. Interview: milieu treatment with borderline patients: the nurse’s role. Journal of Psychosocial Nursing and Mental Health Services. 1984;22:29–36. [PubMed: 6563082]
  • Kerr IB, Dent-Brown K, Parry GD. Psychotherapy and mental health teams. International Review of Psychiatry. 2007;19:63–80. [PubMed: 17365159]
  • Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science: Medicine. 2008;5:e45. [PMC free article: PMC2253608] [PubMed: 18303940]
  • Koons CR, Robins CJ, Tweed JL, et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy. 2001;32:371–390.
  • Krawitz R, Watson C. Borderline Personality Disorder: A Practical Guide to Treatment . Oxford; Oxford University Press; 2000.
  • Kris EB. Day hospitals. Current Therapeutic Research Clinical and Experimental. 1965;7:320–323. [PubMed: 14286214]
  • Kunert HJ, Druecke HW, Sass H, et al. Frontal lobe dysfunctions in borderline personality disorder? Neuropsychological findings. Journal of Personality Disorders. 2003;17:497–509. [PubMed: 14744076]
  • Lafave HG, de Souza HR, Gerber GJ. Assertive community treatment of severe mental illness: a Canadian experience. Psychiatric Services. 1996;47:757–759. [PubMed: 8807692]
  • Lanius R, Tuhan I. Stage-oriented trauma treatment using dialectical behaviour therapy. The Canadian Journal of Psychiatry - La Revue Canadienne de Psychiatrie. 2003;48:126–127. [PubMed: 12655913]
  • Lazzaro TA, Beggs DL, McNeil KA. The development and validation of the self-report test of impulse control. Journal of Clinical Psychology. 1969;25:434–438. [PubMed: 5809423]
  • Lefley HP. From family trauma to family support system, Understanding and Treating Borderline Personality Disorder A Guide for Professionals and Families. Gunderson JG, Hoffman PD, editors. Washington DC: American Psychiatric Publishing; 2005. pp. 131–150.
  • Lehman AF, Dixon LB, Kernan E, et al. A randomized trial of assertive community treatment for homeless persons with severe mental illness. Archives of General Psychiatry. 1997;54:1038–1043. [PubMed: 9366661]
  • Leichsenring F, Masuhr O, Jaeger U, et al. The effectiveness of psychoanalytic-interactional therapy in borderline personality disorder: a study of clinical data. Zeitschrift für Psychosomatische Medizin und Psychotherapie. 2007;53:129–143. [PubMed: 17688783]
  • Lenzenweger MF. Stability and change in personality disorder features: the Longitudinal Study of Personality Disorders. Archives of General Psychiatry. 1999;56:1009–1015. [PubMed: 10565501]
  • Leone NF. Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry. 1982;43:148–150. [PubMed: 7040351]
  • Levy KN. The implications of attachment theory and research for understanding borderline personality disorder. Development and Psychopathology. 2005;17:959–986. [PubMed: 16613426]
  • Lewin J, Sumners D. Successful treatment of episodic dyscontrol with carbamazepine. British Journal of Psychiatry. 1992;161:261–262. [PubMed: 1521112]
  • Lewinsohn PM, Rohde P, Seeley JR, et al. Axis II psychopathology as a function of Axis I disorders in childhood and adolescence. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36:1752–1759. [PubMed: 9401337]
  • Liddel J, Williamson M, Irwig L. Method for Evaluating Research and Guideline Evidence. Sydney: New South Wales Health Department; 1996.
  • Lindsay WR. Personality disorder, Psychiatric and Behavioural Disorders in Intellectual and Developmental Disabilities. Bouras N, Holt G, editors. Cambridge: Cambridge University Press; 2007. pp. 143–153.
  • Linehan MM. Cognitive-Behavioural Treatment of Borderline Personality Disorder . New York: Guilford; 1993.
  • Linehan MM. Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes. Annals of the New York Academy of Sciences. 1997;836:302–328. [PubMed: 9616806]
  • Linehan MM, Heard HL. Treatment History Interview (THI) Seattle, Washington: University of Washington; 1987. Unpublished.
  • Linehan MM, McGhee DE. A cognitive-behavioral model of supervision with individual and group components, Clinical Perspectives on Psychotherapy Supervision. Greben SE, Ruskin R, editors. Washington, DC: American Psychiatric Press; 1994.
  • Linehan MM, Nielsen S. Suicidal Behaviors Questionnaire (SBQ) Seattle, WA: University of Washington; 1981. Unpublished.
  • Linehan MM, Goodstein JL, Nielsen SL, et al. Reasons for staying alive when you are thinking of killing yourself: The Reasons for Living Inventory. Journal of Consulting and Clinical Psychology. 1983;51:276–286. [PubMed: 6841772]
  • Linehan MM, Wagner AW, Cox G. The Parasuicide History Interview: Comprehensive Assessment of Parasuicidal Behaviour. Seattle, Washington: University of Seattle; 1989.
  • Linehan M, Heard HL, Brown M, et al. Parasuicide History Interview (PHI) Seattle, Washington: University of Washington; 1990.
  • Linehan MM, Armstrong HE, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry. 1991;48:1060–1064. [PubMed: 1845222]
  • Linehan MM, Tutek DA, Heard HL, et al. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry. 1994;151:1771–1776. [PubMed: 7977884]
  • Linehan MM, Schmidt H, Dimeff LA, et al. Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addictions. 1999;8:279–292. [PubMed: 10598211]
  • Linehan MM, Dimeff LA, Reynolds SK, et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug and Alcohol Dependence. 2002;67:13–26. [PubMed: 12062776]
  • Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry. 2006;63:757–766. [PubMed: 16818865]
  • Links PS, Steiner M, Mitton J. Characteristics of psychosis in borderline personality disorder. Psychopathology. 1989;22:188–193. [PubMed: 2798708]
  • Links PS, Steiner M, Bojago I, et al. Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders. 1990;4:173–181.
  • Links PS, Eynan R, Heisel MJ, et al. Affective instability and suicidal ideation and behavior in patients with borderline personality disorder. Journal of Personality Disorders. 2007;21:72–86. [PubMed: 17373891]
  • Linn MW, Caffey EM Jr, Klett CJ, et al. Day treatment and psychotropic drugs in the aftercare of schizophrenic patients. A Veterans Administration cooperative study. Archives of General Psychiatry. 1979;36:1055–1066. [PubMed: 224831]
  • Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 2006;26:61–66. [PubMed: 16415708]
  • Loffler-Stastka H, Voracek M, Leithner K, et al. Predicting psychotherapy utilization for patients with borderline personality disorder. Psychotherapy Research. 2003;13:255–264.
  • Lofgren DP, Bemporad J, King J, et al. A prospective follow-up study of so-called borderline children. American Journal of Psychiatry. 1991;148:1541–1547. [PubMed: 1928470]
  • Lopez D, Cuevas P, Gomez A, et al. Transference-focused psychotherapy for borderline personality disorder. A study with female patients. Salud Mental. 2004;27:44–54.
  • Loranger AW, Sartorius N, Janca A. Assessment and Diagnosis of Personality Disorders: The International Personality Disorder Examination (IPDE) New York: Cambridge University Press; 1996.
  • Lorr M, Klett CJ. Inpatient Multidimensional Psychiatric Scale: Manual. Palo Alto, CA: Consulting Psychologists Press; 1966.
  • Luborsky L, Diguer L, Seligman DA, et al. The researcher’s own therapy allegiances: a ‘wild card’ in comparisons of treatment efficacy. Clinical Psychology – Science and Practice. 1999;6:95–106.
  • Lyons-Ruth K, Yellin C, Melnick S, et al. Expanding the concept of unresolved mental states: hostile/helpless states of mind on the Adult Attachment Interview are associated with disrupted mother-infant communication and infant disorganization. Development and Psychopathology. 2005;17:1–23. [PMC free article: PMC1857275] [PubMed: 15971757]
  • Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48:215–221. [PubMed: 15688206]
  • Malm U, Lewander T. Consumer satisfaction in schizophrenia. A 2-year randomized controlled study of two community-based treatment programs. Nordic Journal of Psychiatry. 2001;55:91–96. [PubMed: 11860668]
  • Mann AH, Raven P, Pilgrim J, et al. An assessment of the Standardized Assessment of Personality as a screening instrument for the International Personality Disorder Examination: a comparison of informant and patient assessment for personality disorder. Psychological Medicine. 1999;29:985–989. [PubMed: 10473326]
  • Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. Leeds: NHS Executive; 1996.
  • Markowitz JC, Skodol AE, Bleiberg K. Interpersonal psychotherapy for borderline personality disorder: possible mechanisms of change. Journal of Clinical Psychology. 2006;62:431–444. [PubMed: 16470711]
  • Marx AJ, Test MA, Stein LI. Extrohospital management of severe mental illness. Feasibility and effects of social functioning. Archives of General Psychiatry. 1973;29:505–511. [PubMed: 4748311]
  • Mavromatis M. The diagnosis and treatment of borderline personality disorder in persons with developmental disability: three case reports. Mental Health Aspects of Developmental Disabilities. 2000;3:89–97.
  • McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease. 1980;168:26–33. [PubMed: 7351540]
  • McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States . San Diego, California: Educational and Industrial Testing Service; 1971.
  • McQuillan A, Nicastro R, Guenot F, et al. Intensive dialectical behavior therapy for outpatients with borderline personality disorder who are in crisis. Psychiatric Services. 2005;56:193–197. [PubMed: 15703347]
  • Meares RA, Hobson RF. The persecutory therapist. British Journal of Medical Psychology. 1977;50:349–359. [PubMed: 597485]
  • Meijer M, Goedhart AW, Treffers PD. The persistence of borderline personality disorder in adolescence. Journal of Personality Disorders. 1998;12:13–22. [PubMed: 9573516]
  • Mellsop G, Varghese F, Joshua S, et al. The reliability of axis II of DSM-III. American Journal of Psychiatry. 1982;139:1360–1361. [PubMed: 7124998]
  • Meltzoff J, Blumenthal RL. The Day Treatment Center: Principles, Application and Evaluation . Springfield, Ill: Charles C Thomas; 1966.
  • Merson S, Tyrer P, Onyett S, et al. Early intervention in psychiatric emergencies: a controlled clinical trial. Lancet. 1992;339:1311–1314. [PubMed: 1349990]
  • Mikton C, Grounds A. Cross-cultural clinical judgment bias in personality disorder diagnosis by forensic psychiatrists in the UK: a case-vignette study. Journal of Personality Disorders. 2007;21:400–417. [PubMed: 17685836]
  • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 1979;134:382–389. [PubMed: 444788]
  • Montgomery SA, Roy D, Montgomery DB. The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology. 1983;15:183–188. [PMC free article: PMC1427879] [PubMed: 6824553]
  • Moran P, Jenkins R, Tylee A, et al. The prevalence of personality disorder among UK primary care attenders. Acta Psychiatrica Scandinavica. 2000;102:52–57. [PubMed: 10892610]
  • Moran P, Rendu A, Jenkins R, et al. The impact of personality disorder in UK primary care: a 1-year follow-up of attenders. Psychological Medicine. 2001;31:1447–1454. [PubMed: 11722159]
  • Morant N, King J. A multi-perspective evaluation of a specialist outpatient service for people with personality disorders. The Journal of Forensic Psychiatry and Psychology. 2003;14:44–66.
  • Moreland J, Hendy S, Brown F. The validity of a personality disorder diagnosis for people with an intellectual disability. Journal of Applied Research in Intellectual Disabilities. 2008;21:219–226.
  • Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery and Psychiatry. 2006;77:193–198. [PMC free article: PMC2077578] [PubMed: 16157661]
  • Morse GA, Calsyn RJ, Allen G, et al. Experimental comparison of the effects of three treatment programs for homeless mentally ill people. Hospital Community Psychiatry. 1992;43:1005–1010. [PubMed: 1398563]
  • Morse GA, Calsyn RJ, Klinkenberg WD, et al. An experimental comparison of three types of case management for homeless mentally ill persons. Psychiatric Service. 1997;48:497–503. [PubMed: 9090733]
  • Muijen M, Marks I, Connolly J, et al. Home based care and standard hospital care for patients with severe mental illness: a randomised controlled trial. British Medical Journal. 1992;304:749–754. [PMC free article: PMC1881624] [PubMed: 1571681]
  • Munroe-Blum H, Marziali E. A controlled trial of short-term group treatment for borderline personality disorder. Journal of Personality Disorders. 1995;9:190.
  • NCCMH. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: Gaskell; 2002.
  • NCCMH. Self-harm: The Short-Term Physical and Psychological Management and Secondary Prevention of Self-Harm in Primary and Secondary Care. Leicester & London: British Psychological Society & Gaskell; 2004. [PubMed: 21834185]
  • NCCMH. Depression: Management of Depression in Primary and Secondary Care. Leicester & London: British Psychological Society & Gaskell; 2005.
  • NCCMH. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Leicester and London: British Psychological Society and Gaskell; 2006.
  • Nehls N. Borderline personality disorder: the voice of patients. Research in Nursing and Health. 1999;22:285–293. [PubMed: 10435546]
  • Nezu AM, Perri MG. Social problem-solving therapy for unipolar depression: an initial dismantling investigation. Journal of Consulting and Clinical Psychology. 1989;57:408–413. [PubMed: 2738213]
  • NHS Health Advisory Service. Child and Adolescent Mental Health Services: Together We Stand: The Commissioning, Role and Management of Child and Adolescent Mental Health Services. London: HMSO; 1995.
  • NICE. Self-harm: The Short-Term Physical and Psychological Management and Secondary Prevention of Self-Harm in Primary and Secondary Care, NICE Clinical Guideline 16. London: NICE; 2004. [PubMed: 21834185]
  • NICE. Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-term Management of Insomnia, Technology Appraisal 77. London: NICE; 2004.
  • NICE. Depression: Management of Depression in Primary and Secondary Care, NICE Clinical Guideline 23. London: NICE; 2004.
  • NICE. Guide to the Methods of Technology Appraisal. London: NICE; 2004.
  • NICE. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care . London: NICE; 2006. [PubMed: 21796830]
  • NICE. The Guidelines Manual. London: NICE; 2006. Available at: www​.nice.org.uk.
  • NICE. The Guideline Development Process – An Overview for Stakeholders, the Public and the NHS. Second Edition. London: NICE; 2006.
  • NICE. Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance, NICE Clinical Guideline 45. London: NICE; 2007.
  • NICE. The Guidelines Manual. London: NICE; 2007. Available at: www​.nice.org.uk.
  • NICE. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
  • Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry. 2004;65:1515–1519. [PubMed: 15554765]
  • Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biological Psychiatry. 2005;57:495–499. [PubMed: 15737664]
  • Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. Journal of Affective Disorders. 2005;87:243–252. [PubMed: 15985295]
  • Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry. 2006;163:833–838. [PubMed: 16648324]
  • NIMHE. Breaking the Cycle of Rejection: The Personality Disorder Capabilities Framework. London: Department of Health; 2003.
  • Nordahl HM, Nysaeter TE. Schema therapy for patients with borderline personality disorder: a single case series. Journal of Behaviour Therapy and Experimental Psychiatry. 2005;36:254–264. [PubMed: 15978543]
  • O’Brien M. Doctoral thesis. University of London; 1976. The diagnosis of psychopathy: a study of some characteristics in personality and behaviour of psychopaths referred for treatment to a therapeutic community.
  • Oldham JM. Borderline personality disorder and suicidality. American Journal of Psychiatry. 2006;163:20–26. [PubMed: 16390884]
  • Olsson P, Barth P. New uses of psychodrama. Journal of Operational Psychiatry. 1983;14:95–101.
  • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1982;10:799–812.
  • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychopharmacology Bulletin. 1988;24:97–99.
  • Palmer S, Davidson K, Tyrer P, et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. Journal of Personality Disorders. 2006;20:466–481. [PMC free article: PMC1852260] [PubMed: 17032159]
  • Paris J. Commentary on the American Psychiatric Association guidelines for the treatment of borderline personality disorder: evidence-based psychiatry and the quality of evidence. Journal of Personality Disorders. 2002;16:130–134. [PubMed: 12004489]
  • Paris J. Half in love with easeful death: the meaning of chronic suicidality in borderline personality disorder. Harvard Review of Psychiatry. 2004;12:42–48. [PubMed: 14965853]
  • Paris J. Is hospitalization useful for suicidal patients with borderline personality disorder? Journal of Personality Disorders. 2004;18:240–247. [PubMed: 15237044]
  • Paris J, Zweig-Frank H. A 27-year follow-up of patients with borderline personality disorder. Comprehensive Psychiatry. 2001;42:482–487. [PubMed: 11704940]
  • Paris J, Nowlis D, Brown R. Predictors of suicide in borderline personality disorder. Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie. 1989;34:8–9. [PubMed: 2924254]
  • Paris J, Gunderson J, Weinberg I. The interface between borderline personality disorder and bipolar spectrum disorders. Comprehensive Psychiatry. 2007;48:145–154. [PubMed: 17292705]
  • Pasamanick B, Scarpitti FR, Lefton M, et al. Home vs hosptial care for schizophrenics. Journal of American Medical Association. 1964;187:177–181. [PubMed: 14071885]
  • Pascual JC, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind placebo-controlled randomized study. Journal of Clinical Psychiatry. 2008;69:603–608. [PubMed: 18251623]
  • Payne H. Handbook of Inquiry in the Arts Therapies: One River, Many Currents . London: Jessica Kingsley; 1993.
  • Pearce S, Haigh R. ‘Mini therapeutic communities’: a new development in the United Kingdom. Therapeutic Communities: International Journal for Therapeutic and Supportive Organizations. 2008 in press.
  • Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research. 2001;49:243–251. [PubMed: 11356585]
  • Pfohl B, Coryell W, Zimmerman M, et al. DSM-III personality disorders: diagnostic overlap and internal consistency of individual DSM-III criteria. Comprehensive Psychiatry. 1986;27:21–34. [PubMed: 3948501]
  • Pfohl B, Blum N, Immerman M. Structured Interview for DSM-IV Personality (SIDP-IV) Washington, DC: American Psychiatric Press; 1997.
  • Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196–199. [PubMed: 15470797]
  • Pinto C, Dhavale HS, Nair S, et al. Borderline personality disorder exists in India. Journal of Nervous and Mental Disease. 2000;188:386–388. [PubMed: 10890350]
  • Prendergast N, McCausland J. Dialectic behaviour therapy: a 12-month collaborative program in a local community setting. Behaviour Change. 2007;24:25–35.
  • Quinlivan R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatric Services. 1995;46:365–371. [PubMed: 7788458]
  • Ramklint M, von Knorring AL, von Knorring L, et al. Child and adolescent psychiatric disorders predicting adult personality disorder: a follow-up study. Nordic Journal of Psychiatry. 2003;57:23–28. [PubMed: 12745785]
  • Ramon S, Castillo H, Morant N. Experiencing personality disorder: a participative research. International Journal of Social Psychiatry. 2001;47:1–15. [PubMed: 11694054]
  • Reichborn-Kjennerud T, Czajkowski N, Neale MC, et al. Genetic and environmental influences on dimensional representations of DSM-IV cluster C personality disorders: a population-based multivariate twin study. Psychological Medicine. 2007;37:645–653. [PubMed: 17134532]
  • Rendu A, Moran P, Patel A, et al. Economic impact of personality disorders in UK primary care attenders. British Journal of Psychiatry. 2002;181:62–66. [PubMed: 12091265]
  • Rey JM, Morris-Yates A, Singh M, et al. Continuities between psychiatric disorders in adolescents and personality disorders in young adults. American Journal of Psychiatry. 1995;152:895–900. [PubMed: 7755120]
  • Rinne T, Westenberg HG, den Boer JA, et al. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biological Psychiatry. 2000;47:548–556. [PubMed: 10715361]
  • Rinne T, Van den Brink W, Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry. 2002;159:2048–2054. [PubMed: 12450955]
  • Rosenheck R, Neale M, Gallup P. Community-oriented mental health care: assessing diversity in clinical practice. Psychosocial Rehabilitation Journal. 1993;16:39–50.
  • Royal College of Psychiatrists. DC-LD: Diagnostic Criteria For Psychiatric Disorders For Use With Adults With Learning Disabilities/Mental Retardation . London: Gaskell; 2001.
  • Runeson B, Beskow J. Borderline personality disorder in young Swedish suicides. Journal of Nervous and Mental Disease. 1991;179:153–156. [PubMed: 1997663]
  • Rusch N, van Elst LT, Ludaescher P, et al. A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage. 2003;20:385–392. [PubMed: 14527598]
  • Ryle A. Cognitive Analytic Therapy of Borderline Personality Disorder: the Model and the Method. New York: John Wiley & Sons; 1997.
  • Ryle A, Golynkina K. Effectiveness of time-limited cognitive analytic therapy of borderline personality disorder: factors associated with outcome. British Journal of Medical Psychology. 2000;73:197–210. [PubMed: 10874479]
  • Ryle A, Kerr IB. Introducing Cognitive Analytic Therapy: Principles and Practice. Chichester: John Wiley & Sons; 2002.
  • Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology. 1995;15:23–29. [PubMed: 7714224]
  • Sampson MJ, McCubbin R, Tyrer P. Personality Disorder and Community Mental Health Teams: a Practitioner’s Guide. Chichester: John Wiley & Sons; 2006.
  • Samuels J, Eaton WW, Bienvenu OJ III, et al. Prevalence and correlates of personality disorders in a community sample. British Journal of Psychiatry. 2002;180:536–542. [PubMed: 12042233]
  • Sanderson C, Swenson C, Bohus M. A critique of the American psychiatric practice guideline for the treatment of patients with borderline personality disorder. Journal of Personality Disorders. 2002;16:122–129. [PubMed: 12004488]
  • Sansone RA, Sansone LA, Wiederman MW. Borderline personality disorder and health care utilization in a primary care setting. Southern Medical Journal. 1996;89:1162–1165. [PubMed: 8969349]
  • Sansone RA, Rytwinski D, Gaither GA. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Comprehensive Psychiatry. 2003;44:454–458. [PubMed: 14610722]
  • Schaffer A, Zuker P, Levitt A. Randomized double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorders. 2006;96:95–99. [PubMed: 16820213]
  • Scheirs JGM, Bok S. Psychological distress in caretakers or relatives of patients with borderline personality disorder. International Journal of Social Psychiatry. 2007;53:195–203. [PubMed: 17569405]
  • Schmahl CG, Vermetten E, Elzinga BM, et al. Magnetic resonance imaging of hippocampal and amygdala volume in women with childhood abuse and borderline personality disorder. Psychiatry Research. 2003;122:193–198. [PubMed: 12694893]
  • Schmidt H. Music therapy of borderline personality disorder. PTT: Personlichkeitsstorungen Theorie und Therapie. 2002;6:65–74.
  • Schmidt U, Davidson KM. When Life Is Too Painful: Finding Options after Self Harm . Hove: Psychology Press; 2002.
  • Schotte DE, Clum GA. Suicide ideation in a consultation. Journal of Consulting and Clinical Psychology. 1982;50:690–696. [PubMed: 7142542]
  • Schulz SC, Schulz PM, Dommisse C, et al. Amphetamine response in borderline patients. Psychiatry Research. 1985;15:97–108. [PubMed: 3862151]
  • Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: a variable-dose, 12-week, randomized, double-blind, placebo-controlled study. British Journal of Psychiatry. 2008;193:485–492. [PubMed: 19043153]
  • Sellwood W, Thomas CS, Tarrier N, et al. A randomised controlled trial of home-based rehabilitation versus outpatient-based rehabilitation for patients suffering from chronic schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 1999;34:250–253. [PubMed: 10396166]
  • Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry. 1984;141:1455–1458. [PubMed: 6388363]
  • Shea MT, Stout R, Gunderson J, et al. Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. American Journal of Psychiatry. 2002;159:2036–2041. [PubMed: 12450953]
  • Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. American Journal of Psychiatry. 1991;148:1647–1658. [PubMed: 1957926]
  • SIGN. SIGN 50: A Guideline Developer’s Handbook. Edinburgh Scottish Intercollegiate Guidelines Network; 2001.
  • Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry. 2004;65:379–385. [PubMed: 15096078]
  • Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 1970;212:11–19. [PubMed: 4917967]
  • Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal; with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics. Psychopharmacologia. 1975;43:103–113. [PubMed: 1103205]
  • Singh MM, Kay SR, Opler LA. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping. Psychological Medicine. 1987;17:39–48. [PubMed: 3575576]
  • Singleton N, Meltzer H, Gatward R, et al. Psychiatric Morbidity Among Prisoners: Summary Report. London: Government Statistical Service; 1998.
  • Singleton N, Bumpstead R, O’Brien M, et al. Psychiatric morbidity among adults living in private households, 2000. International Review of Psychiatry. 2003;15:65–73. [PubMed: 12745312]
  • Skodol AE, Stout RL, McGlashan TH, et al. Co-occurrence of mood and personality disorders: a report from the Collaborative Longitudinal Personality Disorders Study (CLPS) Depression and Anxiety. 1999;10:175–182. [PubMed: 10690579]
  • Skodol AE, Gunderson JG, McGlashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. American Journal of Psychiatry. 2002;159:276–283. [PubMed: 11823271]
  • Skodol AE, Pagano ME, Bender DS, et al. Stability of functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder over two years. Psychological Medicine. 2005;35:443–451. [PMC free article: PMC3272760] [PubMed: 15841879]
  • Sledge WH, Tebes J, Rakfeldt J, et al. Day hospital/crisis respite care versus inpatient care, Part I: clinical outcomes. American Journal of Psychiatry. 1996;153:1065–1073. [PubMed: 8678176]

    This is the reference for study ID SLEDGE1996A.

  • Smith K, Shah A, Wright K, et al. The prevalence and costs of psychiatric disorders and learning disabilities. British Journal of Psychiatry. 1995;166:9–18. [PubMed: 7894883]
  • Soeteman DI, Hakkaart-van Roeijn L, Verheul R, et al. The economic burden of personality disorders in mental health care. Journal of Clinical Psychiatry. 2008;69:259–265. [PubMed: 18363454]
  • Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry. 2005;162:1221–1224. [PubMed: 15930077]
  • Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. Journal of Clinical Psychopharmacology. 1989;9:238–246. [PubMed: 2768542]
  • Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry. 1993;50:377–385. [PubMed: 8489326]
  • Soloff PH, Lis JA, Kelly T, et al. Self-mutilation and suicidal behavior in borderline personality disorder. Journal of Personality Disorders. 1994;8:257–267.
  • Soloff PH, Lynch KG, Kelly TM, et al. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study. American Journal of Psychiatry. 2000;157:601–608. [PubMed: 10739420]
  • Spielberger CD, Gorusch RL, Lushene RD. STAI Manual. Palo Alto, CA: Consulting Psychologists Press; 1970.
  • Spielberger CD, Jacobs GA, Russell S, et al. Assessment of anger: the State-Trait Anger Scale, Advances in Personality Assessment. Butcher JN, Spielberger CD, editors. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1983.
  • Springer T, Lohr NA, Buchtel HA, et al. A preliminary report of short-term cognitive-behavioural group therapy for inpatients with personality disorders. Journal of Psychotherapy Practice and Research. 1996;5:57–71. [PMC free article: PMC3330405] [PubMed: 22700265]
  • Stalker K, Ferguson I, Barclay A. ‘It is a horrible term for someone’: service user and provider perspectives on ‘personality disorder’ Disability and Society. 2005;20:359–373.
  • Stein DJ, Hollander E, Cohen L, et al. Neuropsychiatric impairment in impulsive personality disorders. Psychiatry Research. 1993;48:257–266. [PubMed: 8272447]
  • Stein LI, Test MA. Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry. 1980;37:392–397. [PubMed: 7362425]
  • Steinberg BJ, Trestman R, Mitropoulou V, et al. Depressive response to physostigmine challenge in borderline personality disorder patients. Neuropsychopharmacology. 1997;17:264–273. [PubMed: 9326751]
  • Stern A. Psychoanalytic investigation of and therapy in the borderline group of neuroses. Psychoanalysis Quarterly. 1938;7:467–489.
  • Stevenson J, Meares R. An outcome study of psychotherapy for patients with borderline personality disorder. American Journal of Psychiatry. 1992;149:358–362. [PubMed: 1536275]
  • Stevenson J, Meares R, D’Angelo R. Five-year outcome of outpatient psychotherapy with borderline patients. Psychological Medicine. 2005;35:79–87. [PubMed: 15842031]
  • Stone MH. Suicide in borderline and other adolescents. Adolescent Psychiatry. 1992;18:289–305. [PubMed: 1562073]
  • Stone MH. Long-term outcome in personality disorders. British Journal of Psychiatry. 1993;162:299–313. [PubMed: 8453424]
  • Tebartz van Elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biological Psychiatry. 2003;54:163–171. [PubMed: 12873806]
  • Teicher MH, Glod CA, Aaronson ST, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacological Bulletin. 1989;25:535–549. [PubMed: 2631134]
  • Test MA, Knoedler WH, Allness DJ, et al. Long term community care through an assertive continuous treatment team, Advances in Neuropsychiatry and Psychopharmacology Volume 1: Schizophrenia Research. Tamminga CA, Schulz SC, editors. New York: Raven; 1991.
  • Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. Journal of Psychiatric Research. 2001;35:339–345. [PubMed: 11684141]
  • Thompson AR, Donnison J, Warnock-Parkes E, et al. A multidisciplinary community mental health team (CMHT) staff’s experience of a ‘skills’ level training course in cognitive analytic therapy. International Journal of Mental Health Nursing. 2008;17:131–137. [PubMed: 18307602]
  • Tiihonen J, Hallikaien T, Rvvnänen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry. 2003;54:1241–1248. [PubMed: 14643092]
  • Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Comprehensive Psychiatry. 2000;41:416–425. [PubMed: 11086146]
  • Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Archives of Internal Medicine. 2001;58:590–596. [PubMed: 11386989]
  • Torr J. Personality disorder in intellectual disability. Current Opinion in Psychiatry. 2003;16:517–521.
  • Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology. 2003;19:287–291. [PubMed: 15888514]
  • Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. British Journal of Psychiatry. 2007;191:82–83. [PubMed: 17602130]
  • Turner RM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice. 2000;7:413–419.
  • Tyrer P. Borderline personality disorder: a motley diagnosis in need of reform. Lancet. 1999;354:2095–2096. [PubMed: 10609809]
  • Tyrer P. Practice guideline for the treatment of borderline personality disorder: a bridge too far. Journal of Personality Disorders. 2002;16:113–118. [PubMed: 12004486]
  • Tyrer PJ, Remington M. Controlled comparison of day-hospital and outpatient treatment for neurotic disorders. Lancet. 1979;1:1014–1016. [PubMed: 86727]
  • Tyrer P, Alexander MS, Cicchetti D, et al. Reliability of a schedule for rating personality disorders. British Journal of Psychiatry. 1979;135:168–174. [PubMed: 497620]
  • Tyrer P, Merson S, Onyett S, et al. The effect of personality disorder on clinical outcome, social networks and adjustment: a controlled clinical trial of psychiatric emergencies. Psychological Medicine. 1994;24:731–740. [PubMed: 7991755]
  • Tyrer P, Gunderson J, Lyons M, et al. Extent of comorbidity between mental state and personality disorders. Journal of Personality Disorders. 1997;11:242–259. [PubMed: 9348488]
  • Tyrer P, Evans K, Gandhi N, et al. Randomised controlled trial of two models of care for discharged psychiatric patients. British Medical Journal. 1998;316:106–109. [PMC free article: PMC2665389] [PubMed: 9462315]
  • Tyrer P, Jones V, Thompson S, et al. Service variation in baseline variables and prediction of risk in a randomised controlled trial of psychological treatment in repeated parasuicide: the POPMACT Study. International Journal of Social Psychiatry. 2003;49:58–69. [PubMed: 12793516]
  • Tyrer P, Sensky T, Mitchard S. Principles of nidotherapy in the treatment of persistent mental and personality disorders. Psychotherapy and Psychosomatics. 2003;72:350–356. [PubMed: 14526138]
  • Tyrer P, Nur U, Crawford M, et al. The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning. International Journal of Social Psychiatry. 2005;51:265–275. [PubMed: 16252794]
  • Vaglum P, Friis S, Irion T, et al. Treatment response of severe and nonsevere personality disorders in a therapeutic community day unit. Journal of Personality Disorders. 1990;4:161–172.
  • Van Asselt ADI, Dirksen CD, Arntz A, et al. The cost of borderline personality disorder: societal cost of illness in BPD-patients. European Psychiatry. 2007;22:354–361. [PubMed: 17544636]
  • Van Asselt ADI, Dirksen CD, Arntz A, et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. British Journal of Psychiatry. 2008;192:450–457. [PubMed: 18515897]
  • Van den Bosch LMC, Verheul R, Schippers GM, et al. Dialectical behavior therapy of borderline patients with and without substance use problems: implementation and long-term effects. Addictive Behaviors. 2002;27:911–923. [PubMed: 12369475]
  • Van Kessel K, Lambie I, Stewart MW. Impact of brief planned admissions on inpatient mental health unit utilisation for people with a diagnosis of borderline personality disorder. New Zealand Journal of Psychology. 2002;31:93–97.
  • Vieta E, Goikolea JM, Olivares JM, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. Journal of Clinical Psychiatry. 2003;64:834–839. [PubMed: 12934986]
  • Waller D, Gilroy A. Art Therapy: A Handbook . Buckingham: Open University Press; 1992.
  • Warren F, Evans C, Dolan B, et al. Impulsivity and self-damaging behaviour in severe personality disorder: the impact of democratic therapeutic community treatment. Therapeutic Communities: the International Journal for Therapeutic and Supportive Organizations. 2004;25:55–71.
  • Warren F, Zaman S, Dolan B, et al. Eating disturbance and severe personality disorder: outcome of specialist treatment for severe personality disorder. European Eating Disorders Review. 2006;14:69–78.
  • Waters E, Merrick S, Treboux D, et al. Attachment security in infancy and early adulthood: a twenty-year longitudinal study. Child Development. 2000;71:684–689. [PubMed: 10953934]
  • Weinberg I, Gunderson JG, Hennen J, et al. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. Journal of Personality Disorders. 2006;20:482–492. [PubMed: 17032160]
  • Weinfield NS, Sroufe LA, Egeland B. Attachment from infancy to early adulthood in a high-risk sample: continuity, discontinuity, and their correlates. Child Development. 2000;71:695–702. [PubMed: 10953936]
  • Weinstein W, Jamison KL. Retrospective case review of lamotrigine use for affective instability of borderline personality disorder. CNS Spectrums: The International Journal of Neuropsychiatric Medicine. 2007;12:207–210. [PubMed: 17329981]
  • Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Archives of General Psychiatry. 1976;33:1111–1115. [PubMed: 962494]
  • Weldon E, Clarkin JE, Hennessy JJ, et al. Day hospital versus outpatient treatment: a controlled study. Psychiatric Quarterly. 1979;51:144–150. [PubMed: 482458]
  • Westen D. Divergences between clinical and research methods for assessing personality disorders: implications for research and the evolution of axis II. American Journal of Psychiatry. 1997;154:895–903. [PubMed: 9210738]
  • Westen D, Shedler J. Personality diagnosis with the Shedler-Westen assessment procedure (SWAP): integrating clinical and statistical measurement and prediction. Journal of Abnormal Psychology. 2007;116:810–822. [PubMed: 18020727]
  • White CN, Gunderson JG, Zanarini MC, et al. Family studies of borderline personality disorder: a review. Harvard Review of Psychiatry. 2003;11:8–19. [PubMed: 12866737]
  • Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341–1345. [PubMed: 15110490]
  • WHOQOL group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Social Sciences and Medicine. 1998;46:1569–1585. [PubMed: 9672396]
  • Wilberg T, Friis S, Karterud S, et al. Outpatient group psychotherapy: a valuable continuation treatment for patients with borderline personality disorder treated in a day hospital? A 3-year follow-up study. Nordic Journal of Psychiatry. 1998;52:213–222.
  • Wilson M. A four-stage model for management of borderline personality disorder in people with mental retardation. Mental Health Aspects of Developmental Disabilities. 2001;4:68–76.
  • World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
  • Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64:961–965. [PubMed: 15781808]
  • Yen S, Shea MT. Recent developments in research of trauma and personality disorders. Current Psychiatry Reports. 2001;3:52–58. [PubMed: 11177760]
  • Yen S, Shea MT, Sanislow CA, et al. Borderline personality disorder criteria associated with prospectively observed suicidal behavior. American Journal of Psychiatry. 2004;161:1296–1298. [PubMed: 15229066]
  • Yen S, Pagano ME, Shea MT, et al. Recent life events preceding suicide attempts in a personality disorder sample: findings from the collaborative longitudinal personality disorders study. Journal of Consulting and Clinical Psychology. 2005;73:99–105. [PMC free article: PMC3276403] [PubMed: 15709836]
  • Young D, Gunderson J. Family images of borderline adolescents. Psychiatry: Interpersonal and Biological Processes. 1995;58:164–172. [PubMed: 7568538]
  • Young J. Cognitive Therapy for Personality Disorders: A Schema-Focused Approach. Saratosa: Professional Resource Exchange; 1990.
  • Young J, Klosko JS. Reinventing Your Life: the Breakthrough Program to End Negative Behavior . . . and Feel Great Again. New York: Plume Books; 1994.
  • Young JE, Klosko JS, Weishaar ME. Schema Therapy: A Practitioner’s Guide. NewYork: Guilford Press; 2003.
  • Young SN, Leyton M. The role of serotonin in human mood and social interaction: insight from altered tryptophan levels. Pharmacology Biochemistry and Behavior. 2002;71:857–865. [PubMed: 11888576]
  • Yudofsky SC, Silver JM, Jackson W, et al. The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry. 1986;143:35–39. [PubMed: 3942284]
  • Zanarini M. Diagnostic Interview for Personality Disorders (DIPD) Belmont, MA: McLean Hospital; 1983.
  • Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry. 2001;62:849–854. [PubMed: 11775043]
  • Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. American Journal of Psychiatry. 2003;160:167–169. [PubMed: 12505817]
  • Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry. 1998;155:1733–1739. [PubMed: 9842784]
  • Zanarini MC, Frankenburg FR, Reich DB, et al. Biparental failure in the childhood experiences of borderline patients. Journal of Personality Disorders. 2000;14:264–273. [PubMed: 11019749]
  • Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. American Journal of Psychiatry. 2003;160:274–283. [PubMed: 12562573]
  • Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry. 2004;65:903–907. [PubMed: 15291677]

    This is the reference for Study ID ZANARINI2004.

  • Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. Journal of Clinical Psychiatry. 2004;65:28–36. [PubMed: 14744165]
  • Zelkowitz P, Paris J, Guzder J, et al. A five-year follow-up of patients with borderline pathology of childhood. Journal of Personality Disorders. 2007;21:664–674. [PubMed: 18072867]
  • Zimmerman M. Diagnosing personality disorders: a review of issues and research methods. Archives of General Psychiatry. 1994;51:225–245. [PubMed: 8122959]
  • Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983;67:361–370. [PubMed: 6880820]
  • Zisook S, Goff A, Sledge P, et al. Reported suicidal behavior and current suicidal ideation in a psychiatric outpatient clinic. Annals of Clinical Psychiatry. 1994;6:27–31. [PubMed: 7951642]
  • Zweig-Frank H, Paris J. Parents’ emotional neglect and overprotection according to the recollections of patients with borderline personality-disorder. American Journal of Psychiatry. 1991;148:648–651. [PubMed: 2018169]
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.

NICE (National Institute for Health and Care Excellence)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...